Your browser doesn't support javascript.
loading
Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular Mechanisms.
Zhou, Zheng; Hu, Taishan; Zhou, Xue; Wildum, Steffen; Garcia-Alcalde, Fernando; Xu, Zhiheng; Wu, Daitze; Mao, Yi; Tian, Xiaojun; Zhou, Yuan; Shen, Fang; Zhang, Zhisen; Tang, Guozhi; Najera, Isabel; Yang, Guang; Shen, Hong C; Young, John A T; Qin, Ning.
Afiliación
  • Zhou Z; Roche Pharma Research and Early Development, Chemical Biology, Roche Innovation Center Shanghai, Shanghai, 201203, China.
  • Hu T; Roche Pharma Research and Early Development, Medicinal Chemistry, Roche Innovation Center Shanghai, Shanghai, 201203, China.
  • Zhou X; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center Shanghai, Shanghai, 201203, China.
  • Wildum S; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.
  • Garcia-Alcalde F; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.
  • Xu Z; Roche Pharma Research and Early Development, Chemical Biology, Roche Innovation Center Shanghai, Shanghai, 201203, China.
  • Wu D; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center Shanghai, Shanghai, 201203, China.
  • Mao Y; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center Shanghai, Shanghai, 201203, China.
  • Tian X; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center Shanghai, Shanghai, 201203, China.
  • Zhou Y; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center Shanghai, Shanghai, 201203, China.
  • Shen F; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center Shanghai, Shanghai, 201203, China.
  • Zhang Z; Roche Pharma Research and Early Development, Medicinal Chemistry, Roche Innovation Center Shanghai, Shanghai, 201203, China.
  • Tang G; Roche Pharma Research and Early Development, Medicinal Chemistry, Roche Innovation Center Shanghai, Shanghai, 201203, China.
  • Najera I; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.
  • Yang G; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center Shanghai, Shanghai, 201203, China.
  • Shen HC; Roche Pharma Research and Early Development, Medicinal Chemistry, Roche Innovation Center Shanghai, Shanghai, 201203, China.
  • Young JA; Roche Pharma Research and Early Development, Immunology, Inflammation and Infectious Diseases Discovery and Translational Area, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.
  • Qin N; Roche Pharma Research and Early Development, Chemical Biology, Roche Innovation Center Shanghai, Shanghai, 201203, China.
Sci Rep ; 7: 42374, 2017 02 13.
Article en En | MEDLINE | ID: mdl-28205569
Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) are promising non-nucleos(t)ide HBV replication inhibitors. HAPs are known to promote core protein mis-assembly, but the molecular mechanism of abnormal assembly is still elusive. Likewise, the assembly status of core protein induced by SBA remains unknown. Here we show that SBA, unlike HAP, does not promote core protein mis-assembly. Interestingly, two reference compounds HAP_R01 and SBA_R01 bind to the same pocket at the dimer-dimer interface in the crystal structures of core protein Y132A hexamer. The striking difference lies in a unique hydrophobic subpocket that is occupied by the thiazole group of HAP_R01, but is unperturbed by SBA_R01. Photoaffinity labeling confirms the HAP_R01 binding pose at the dimer-dimer interface on capsid and suggests a new mechanism of HAP-induced mis-assembly. Based on the common features in crystal structures we predict that T33 mutations generate similar susceptibility changes to both compounds. In contrast, mutations at positions in close contact with HAP-specific groups (P25A, P25S, or V124F) only reduce susceptibility to HAP_R01, but not to SBA_R01. Thus, HAP and SBA are likely to have distinctive resistance profiles. Notably, P25S and V124F substitutions exist in low-abundance quasispecies in treatment-naïve patients, suggesting potential clinical relevance.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirimidinas / Replicación Viral / Benzamidas / Virus de la Hepatitis B Límite: Humans Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirimidinas / Replicación Viral / Benzamidas / Virus de la Hepatitis B Límite: Humans Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido